[VERIFY: confirm GHK-Cu plasma level decline figures with published source before publishing] BPC-157 repairs the specific area that is damaged
Semaglutide and tirzepatide studies show roughly two-thirds of lost weight returning within a year, with most regain in the first months and about one-third to 40% of the loss still held at one year. Retatrutide may produce greater regain pressure because its glucagon support for resting metabolism fades while appetite returns
Maximum weight reduction is the primary endpoint: If a study or personal biohacking protocol prioritises achieving the largest possible adiposity change, retatrutides 9.3 percentage point advantage over semaglutide (24.2% vs 14.9% at maximum tolerated doses) justifies the 2843 weekly cost increment
Whether chronic use affects normal age-related changes in metabolism, body composition, or health cannot be determined from current data
Greater Trochanteric Pain Syndrome This condition, previously called trochanteric bursitis, actually involves gluteal tendinopathy more often than pure bursitis
Lancet 390 (10113), 26272642